8-K: Harrow Inc. Reports Strong 2023 Revenue Growth and Provides Business Update

Harrow Inc. announced a 47% increase in revenue for 2023, reaching $130.2 million, alongside significant growth in Adjusted EBITDA.

Summary

• Harrow Inc. reported its financial results for the year and quarter ended December 31, 2023, along with a corporate update.
• Full-year 2023 revenues reached $130.2 million, a 47% increase compared to $88.6 million in 2022.
• The company experienced a GAAP net loss of $(24.4 million) in 2023, compared to a loss of $(14.1 million) in the previous year.
• Adjusted EBITDA for 2023 was $28.1 million, a 116% increase from $13.0 million in 2022.
• Cash from operating activities was $3.8 million for the year.
• GAAP gross margin was 70%, slightly down from 71% in the prior year, while core gross margin increased to 77% from 73%.
• The company ended the year with $83 million in cash and cash equivalents, including investments in Eton Pharmaceuticals.
• Harrow's fourth-quarter revenue was $36.4 million, an 83% increase year-over-year.
• The company is focused on growing its branded product portfolio, including IHEEZO, VEVYE, and TRIESENCE.
• Harrow expects 2024 revenues to be at least $180 million.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, significant EBITDA improvement, and successful product launches. While there are challenges, the overall tone is optimistic about the company's future prospects.

Positives

• Harrow achieved significant revenue growth in 2023, demonstrating strong market traction.
• The substantial increase in Adjusted EBITDA indicates improved profitability.
• The company's core gross margin expansion reflects efficient operations.
• The successful launch of VEVYE and its high refill rate are positive indicators of market acceptance.
• The addition of over 40 million covered lives for VEVYE enhances its accessibility.
• The progress in TRIESENCE production and the planned re-launch are promising.
• The turnaround of ImprimisRx and its expected revenue growth contribute to overall positive performance.
• Harrow's strong cash position provides financial stability and flexibility.
• The company's strategic focus on branded products is expected to drive future growth.
• The company has a strong management team and is attracting experienced talent.

Negatives

• Harrow reported a GAAP net loss of $(24.4 million) for 2023, an increase from the previous year's loss.
• The company experienced a decrease in cash and cash equivalents from $96.3 million to $74.1 million.
• The initial request to CMS for IHEEZO's ASP was not acted upon, although it has since been added.
• The Change Healthcare cybersecurity attack has temporarily impacted IHEEZO sales and cash collection.
• The company's stock price experienced fluctuations throughout 2023, ending near its lowest point for the year.
• The company's selling, general, and administrative expenses increased significantly due to investments in the VEVYE launch and other factors.
• Research and development costs also increased due to the build-out of medical and clinical affairs teams and other factors.
• The company experienced a GAAP operating loss of ($4.9) million for the fourth quarter of 2023.
• Core net loss was $(4.4) million for the fourth quarter of 2023 compared with core net income of $2.1 million for the fourth quarter of 2022.
• The company is still working to optimize insurance provider contracting for VEVYE.

Risks

• The company faces risks related to the successful commercialization of its products.
• There are risks associated with the development and manufacturing of pharmaceutical products.
• Competition from other pharmaceutical companies and pharmacies poses a challenge.
• General economic conditions, including inflation and supply chain issues, could impact the business.
• Regulatory and legal risks related to pharmacy operations and the pharmaceutical industry are present.
• The company's ability to manage growth and integrate acquisitions is crucial.
• The company is dependent on physician interest and market acceptance of its products.
• The company's debt levels could pose a risk to its financial stability.
• The company's reliance on third-party manufacturers and suppliers could lead to disruptions.
• The company's stock price may be volatile and subject to market fluctuations.

Future Outlook

Harrow expects 2024 revenues to be at least $180 million, with stronger revenues in the second half of the year due to traditional pharma revenue seasonality. The company anticipates continued growth from its branded products and a successful re-launch of TRIESENCE.

Management Comments

• Mark L. Baum, CEO of Harrow, stated that the company has transformed from a focus on compounded products to a leader in the North American ophthalmic pharmaceuticals market.
• The CEO expressed confidence in the company's products, resources, and people to take advantage of future opportunities.
• The CEO noted that the VEVYE launch is exceeding expectations and that prescribers are seeing outstanding results.
• The CEO mentioned that the company is working to re-launch TRIESENCE and is confident in its market potential.
• The CEO stated that ImprimisRx is back on track and is expected to grow revenues by 10% or more in 2024.
• The CEO emphasized that Harrow is focused on economic accomplishment and building long-term value.
• The CEO mentioned that he has never sold a share of Harrow stock and has recently purchased shares.

Industry Context

Harrow's expansion into branded ophthalmic pharmaceuticals aligns with a broader industry trend of companies seeking to diversify their product portfolios and capture higher-margin opportunities. The company's focus on innovative products and market access strategies positions it to compete effectively in the growing ophthalmic market.

Comparison to Industry Standards

• Harrow's 47% revenue growth significantly outpaces the average growth rate for the pharmaceutical industry, which typically ranges from 5% to 10% annually.
• The 116% increase in Adjusted EBITDA is exceptional compared to industry averages, indicating strong operational efficiency and profitability improvements.
• Harrow's core gross margin of 77% is competitive with leading pharmaceutical companies, such as Alcon (ALC) and Bausch Health (BHC), which often report gross margins in the 70-80% range.
• The successful launch of VEVYE and its high refill rate are comparable to the initial uptake of other successful dry eye disease treatments like Xiidra (by Novartis) and Restasis (by Allergan, now AbbVie), which also saw strong initial adoption.
• Harrow's focus on branded products and market access strategies mirrors the approach of larger pharmaceutical companies, such as AbbVie (ABBV) and Johnson & Johnson (JNJ), which prioritize product innovation and patient access.
• The company's investment in a dedicated sales force for VEVYE is similar to the strategies employed by other pharmaceutical companies launching new products, such as Sun Pharma's Cequa launch.
• Harrow's efforts to secure insurance coverage for VEVYE are consistent with industry best practices, as seen with companies like Regeneron (REGN) and their efforts to secure coverage for Eylea.
• The company's focus on innovation within its ImprimisRx business, such as the repackaged Vigamox, is similar to the strategies of compounding pharmacies like Fagron, which focus on developing new formulations and delivery methods.
• Harrow's strategic partnerships, such as the out-licensing of Canadian rights to Apotex, are common in the pharmaceutical industry, as seen with companies like Teva (TEVA) and their various licensing agreements.
• The company's investment in Melt Pharmaceuticals and its non-opioid sedation platform is a unique approach that could differentiate it from competitors, similar to how companies like Pacira BioSciences (PCRX) have focused on non-opioid pain management.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the company's strong revenue growth and improved profitability.
• Employees will have opportunities for growth and development within the company.
• Customers will have access to innovative and effective ophthalmic pharmaceutical products.
• Suppliers will benefit from the company's increased demand for its products.
• Creditors will be reassured by the company's strong financial performance.

Next Steps

• Harrow will continue to focus on the commercialization of IHEEZO, VEVYE, and TRIESENCE.
• The company will work to resolve the issues caused by the Change Healthcare cybersecurity attack.
• Harrow will continue to seek insurance coverage for VEVYE.
• The company will proceed with the SPARE Study for IHEEZO.
• Harrow will continue to improve the TRIESENCE production process and re-launch the product.
• The company will continue to innovate within its ImprimisRx business.
• Harrow will remain open to strategic M&A opportunities.
• The company will provide an update in the next Letter to Stockholders in May 2024.

Key Dates

Keywords

ophthalmic pharmaceuticals, revenue growth, adjusted EBITDA, branded products, IHEEZO, VEVYE, TRIESENCE, ImprimisRx, dry eye disease, compounding, market access, CMS, financial results, pharmaceuticals, eyecare